Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15450979 | 0.85 | — | — | |
| SCHEMBL15450975 | 0.85 | — | — | |
| SCHEMBL12654315 | 0.82 | — | — | |
| SCHEMBL6847029 | 0.75 | — | — | |
| SCHEMBL14530586 | 0.73 | PTPN1 (0.31) | PTPN1 | |
| SCHEMBL12026420 | 0.73 | KDM5B (0.37) | PTPN1 | |
| SCHEMBL21945926 | 0.73 | GABBR1 (0.31) | PTPN1 | |
| SCHEMBL4953851 | 0.73 | PTPN1 (0.31) | PTPN1 | |
| SCHEMBL12603760 | 0.72 | TRPV3 (0.38) | — | |
| SCHEMBL14606913 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352338-B2 | Substituted isoindolinones | BIOTHERYX, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-10870661-B2 | Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| US-20200325114-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200055873-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20180162876-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180162876-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9975906-B2 | Tricyclic heterocycle derivatives having HIV replication inhibitory effect | SHIONOGI & CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975906-B2 | Tricyclic heterocycle derivatives having HIV replication inhibitory effect | SHIONOGI & CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170107234-A1 | TRICYCLIC HETEROCYCLE DERIVATIVES HAVING HIV REPLICATION INHIBITORY EFFECT | SHIONOGI & CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107234-A1 | TRICYCLIC HETEROCYCLE DERIVATIVES HAVING HIV REPLICATION INHIBITORY EFFECT | SHIONOGI & CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055873-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | NR4A3, CCR3, NCOA3 | PTPN1 1048/4885 |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | PTPN1 3659/4885 |
| US-20180162876-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | NR4A3, CCR3, NCOA3 | PTPN1 1048/4885 |
| US-20170107234-A1 | TRICYCLIC HETEROCYCLE DERIVATIVES HAVING HIV REPLICATION INHIBITORY EFFECT | NR4A1, NR4A3, NR0B1 | PTPN1 585/4885 |
| US-10870661-B2 | Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity | NR4A3, CCR3, NCOA3 | PTPN1 1048/4885 |
| US-20200325114-A1 | SUBSTITUTED ISOINDOLINONES | BRCA1, FANCI, GOT2 | PTPN1 4202/4885 |
| US-11352338-B2 | Substituted isoindolinones | BRCA1, FANCI, GOT2 | PTPN1 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.